EMEA rejects insulin glargine cancer link

Available data do not support a link between insulin glargine (Lantus) and an increased risk of developing cancer, the European Medicines Agency (EMEA) has concluded.

The EMEA investigated the possibility of a link between insulin glargine use and cancer risk after three studies highlighted safety concerns.

Following a review of the data, the agency's Committee for Medicinal Products for Human Use (CHMP) said: ‘The available data does not provide a cause for concern and that changes to the prescribing advice are therefore not necessary.'

The committee said that methodological limitations meant that the studies were inconclusive and did not allow a relationship between insulin glargine and cancer to be confirmed or excluded.

The committee has asked Sanofi-Aventis, Lantus's licence-holder, to develop a strategy for conducting further research into the product's safety profile.


More news from 27 July

BMA guidance on fees for non-NHS work
Half of practices given go-ahead to upload summary care records
DoH primary care czar visits award-winning practice
RCN ends opposition to assisted suicide

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in